Semi-annual report — FY2026 H1
What DAIKEN MEDICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-02View the original on EDINET
How much it says
42Thin
What moved here
11named for the first time
Its own wording
10terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, there were no new business or other risks and no material changes to the management policies, management strategies or other matters. Total R&D expenses were ¥163 million. Revenue was ¥5,097 million, up 0.8% year on year, while operating profit, ordinary profit and interim net profit were below the year-earlier levels due to higher material costs and increased personnel expenses.
Komori's summary of this document, not the document's own words.42Thin
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
45
Typical
70
Detailed
50
Typical
0
Almost nothing
68
Detailed
27
Almost nothing
0
Almost nothing
0
Almost nothing
50
Typical
R&D spend2億円Money spent making new things.
Cash left over-2億円Cash from the business, less what went into equipment.
Spent on equipment2億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.